WBB Securities

@wbbsec

WBB Securities is a leading investment management, investment banking, and equity research firm focused in biotech, medtech and specialty pharma.

San Diego, CA
Vrijeme pridruživanja: ožujak 2014.

Tweetovi

Blokirali ste korisnika/cu @wbbsec

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @wbbsec

  1. 3. velj
    Poništi
  2. 11. pro 2019.
    Poništi
  3. 14. stu 2019.
    Poništi
  4. 10. lis 2019.

    How will a Hard- affect the health of Britons? You need only look at the UK travelers stranded by the travel bankruptcy & think will people seeking healthcare be stranded in a similar way, but with no "Rescue Flights" to help them?

    Poništi
  5. 29. srp 2019.

    With record setting temperatures across the globe and financial heat on this was the answer to Pfizer's patent cliff. A brief story in Forbes, on what is the reason behind the - merger. The answer - China and loss of patents!

    Poništi
  6. 27. lip 2019.

    The future is in doubt for cheaper versions of biologic drugs - "It will take another recession and a surge of unemployed, uninsured patients for the government to enact major changes to boost biosimilar use."

    Poništi
  7. 18. lip 2019.

    A prognosis on , who will survive? Which antibiotics company will show resistance to the bacterial and captial markets onslaught? After the TTPH realization that sales are the only short term answer, what can we expect from its competitors?

    Poništi
  8. 10. svi 2019.

    What will the future for and the fight against look like? Here's insight into challenging the system by the Director of BARDA, Dr. Rick Bright.

    Poništi
  9. 8. tra 2019.

    Just published in STAT: Before tomorrow's PBM Senate hearings, a few ideas on how the future of Orphan Drugs can change the high prices of Pharmaceutical and Biotech therapies. How cell and gene therapies might allow the rise of value-based agreements

    Poništi
  10. 30. sij 2019.

    This piece illustrates how little biotech and their VCs appreciate or even understand the validation that real peer-review journals confer on their technology and ultimately their franchise success.

    Tweet je nedostupan.
    Poništi
  11. 28. pro 2018.

    The hope of CRISPR is the stuff that BioTech dreams are made of, however, the risks are stacked ten deep against it. With clinical trials, FDA approval, reimbursement and patient treatment these investments are not for the faint of heart.

    Poništi
  12. 5. pro 2018.

    When Cancer Used to be simple # # The Future Of Cancer Care: A 50 Minute Discussion At Forbes Steve Brozak - Forbes Contributor

    Poništi
  13. 9. stu 2018.

    It’s not whether an outbreak will occur, but which one among hundreds of threats and when. How partnerships will meet future healthcare risks in the US.

    Poništi
  14. 12. lis 2018.
    Poništi
  15. 7. lip 2018.

    Rebalancing Novo Nordisk: The company has a hold on the diabetes market, but can it diversify into new areas of medicine? A snapshot of the company and its need for M&A after its attempt to acquire Ablynx failed. via

    Poništi
  16. proslijedio/la je Tweet
    17. svi 2018.

    Health Care Disruptors: The New Normal panel going on right now! Ameer Ali Steve Brozak Chris Loughlin Thomas. O’Connor Cliff Goodman

    Poništi
  17. proslijedio/la je Tweet

    Investors looking for new places to deploy capital. Does this interest in art signal a stock market crash? New signs of confidence in the art market via

    Poništi
  18. 2. velj 2018.

    Are Modern Urgent Care Centers Changing The Way Is Delivered? via

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·